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Abstract
INTRODUCTION: Akathisia continues to present a significant challenge in clinical practice. As a class, 
“atypical” or second-generation antipsychotics (SGAs) are the mainstay of treatment for schizophrenia 
and are commonly used to treat mood disorders. These medications have traditionally been distinguished 
from first-generation antipsychotics by their lowered risk of extrapyramidal side effects (EPS) such as 
dystonia, dyskinesia, akathisia, and pseudoparkinsonism. However, the occurrence of EPS, particularly 
akathisia, has been demonstrated to some degree in all commercially available SGAs.
OBJECTIVE: This review examines the incidence of akathisia in nine newer SGAs in patients with 
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METHODS: We performed a search of PubMed, ClinicalTrials.gov, Cochrane Central Register, Google 
Scholar, as well as manufacturer websites and product labeling for published and unpublished clinical 
trials, meta-analyses, and systematic reviews. Studies evaluating adult patients with schizophrenia, 
bipolar disorder, or MDD were eligible for inclusion. Data on treatment emergent akathisia rates were 
gathered from each study and potential dose-response relationships was explored.
RESULTS: A total of 177 studies were included in this review, comprising 58,069 patients across 414 
treatment arms. Compared to placebo with a composite 3.7% incidence of akathisia, individual SGAs 
produced akathisia at total composite rates ranging from 2.9% to 13.0% across the included studies. High 
doses of an SGA were generally associated with an increased risk of akathisia.
CONCLUSION: Clinicians should consider risk of akathisia when choosing a treatment option and 
monitor for akathisia in patients beginning therapy with an SGA or following a dose increase of the SGA.
KEY WORDS: akathisia, antipsychotics, schizophrenia, bipolar disorder, major depressive disorder 
Introduction
Akathisia is a movement disorder characterized by distressing feelings of restlessness or inner tension 
generally associated with the use of “typical” or first-generation antipsychotics (FGAs). Despite its 
recognition for being the most common movement-related adverse effect of antipsychotics, historically 
akathisia has been both under- and mis-diagnosed in clinical practice – likely due to its subjective 
nature.1–3 The unrelenting urge to move often manifests as increased motor activity consisting of 
complex, repetitive movements, though in some patients it remains internalized. Akathisia has been 
identified as a principal cause of medication non-adherence in patients with schizophrenia, and is 
associated with treatment emergent suicidality.4,5 This adverse effect presents a substantial treatment 
challenge in patients with schizophrenia and mood disorders such as bipolar disorder and major 
depressive disorder (MDD). For these reasons, the likelihood of akathisia  is an important consideration in 
the choice of an antipsychotic agent.6,7  
Different classifications of drug-induced akathisia have been proposed based upon the timing of onset 
and clinical profile; these include acute, chronic, withdrawal, and even tardive akathisia. Acute akathisia 
typically develops within a few days to two weeks following initiation, dose escalation, or switch to a high-
potency antipsychotic agent.3,6 If symptoms of akathisia develop after this time frame, or are consistently 
present for numerous months, it is classified as chronic akathisia.6 After the discontinuation or dose 
reduction of an antipsychotic medication, a patient may experience withdrawal akathisia.7 However, if 
symptoms do not resolve within 6 weeks, or a patient experiences a delayed onset of symptoms (1-3 
months after treatment initiation), it would be considered tardive akathisia.7 The Barnes Akathisia Rating 
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As a class, “atypical” or second-generation antipsychotics (SGAs) are the mainstay of treatment for 
schizophrenia and are commonly used to treat mood disorders.6,9,10 These medications have traditionally 
been distinguished from FGAs by their lower risk of extrapyramidal side effects (EPS) such as dystonia, 
dyskinesia, akathisia, and pseudoparkinsonism.11,12 However EPS, particularly akathisia, occurs, to some 
degree, with all commercially available SGAs.12–17 Evidence from clinical trials on the risk of akathisia in 
individual SGAs has been largely inconsistent with questionable applicability to real-world practice due to 
issues with carryover effects and non-equivalent doses being studied.16 Furthermore, previous meta-
analyses and systematic reviews comparing the safety and tolerability of FGAs and SGAs have found 
little evidence to support the notion that as a class, SGAs pose a reduced risk for EPS compared to 
FGAs.7,9,13–15 However, high potency first-generation antipsychotics tend to pose the greatest risk for 
EPS.13
Rates of akathisia with older SGAs, such as clozapine, olanzapine and quetiapine, have been 
comprehensively reviewed and published.3 Although it is generally accepted that clozapine and 
quetiapine have the lowest rates of akathisia, studies included in that review reported rates of akathisia 
from 0% to 10% for clozapine, olanzapine and quetiapine.3 This review examines the literature on the use 
of nine newer SGAs (Table 1) with regard to incidence of akathisia in patients with schizophrenia, bipolar 
disorder, and depression based on clinical trials involving FDA approved indications respective to each 
agent. 
Methods
A review of the literature was conducted to identify studies evaluating adult patients receiving 
maintenance treatment for schizophrenia, bipolar disorder, or MDD with one of the nine antipsychotics 
listed in Table 1. Both open-label and double-blind, randomized controlled trials (RCTs) which compared 
doses of at least one of the aforementioned SGAs with another SGA, placebo, or an FGA were included. 
All flexible-dose studies were included; fixed-dose studies evaluating target doses up to the maximum 
approved by the Food and Drug Administration (FDA) and established by the international consensus 
study of antipsychotic dosing were also included.18 Each study was evaluated for data on treatment 
emergent akathisia rates in study participants.
The authors searched PubMed, ClinicalTrials.gov, Cochrane Central Register, Google Scholar, as well as 
manufacturer websites and product labeling for published and unpublished clinical trials, meta-analyses, 
and systematic reviews using search terms consisting of the generic names of SGAs along with the terms 
“schizophrenia”, “bipolar”, or “major depressive disorder”. Additionally, the reference lists of all studies 
identified in the search were inspected for more trials. Studies were excluded if they involved patients 
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Studies that specifically assessed akathisia, with a Global item score of 2 or greater on the BARS, were 
included, whereas those that only reported generalized results for EPS were excluded. Studies evaluating 
akathisia largely rely on the BARS. The BARS is a four-item scale that accounts for both the objective 
(i.e., observable) features and the subjective experience of akathisia. The objective item assesses the 
type and frequency of fidgety, restless movements, whereas the subjective items evaluate the intensity of 
the feelings of restlessness as well as the level of associated distress. Together, this allows for an overall 
measure of severity to be made using the Global Clinical Assessment item, comprised of clinically 
relevant severity classifications scored on a five-point scale: 0 = absent; 1 = questionable; 2 = mild 
akathisia; 3 = moderate akathisia; 4 = marked akathisia; and 5 = severe akathisia. A Global item score of 
2 or greater on the BARS meets diagnostic threshold for akathisia.2,19 
An analysis of potential dose-response relationships was explored based on expert opinion from an 
international consensus study of antipsychotic dosing and using the low- and high-dosage cutoffs (Table 
2), to detect inequalities in dosing in the multiple-treatments meta-analysis study comparing efficacy and 
tolerability of 15 antipsychotics.13,18 
Results
A total of 177 studies with 58,069 participants across 414 treatment arms were included in the 
comparative analysis (Appendix S1).32-111 Of these, the breakdown for numbers of studies including each 
medication are as follows: aripiprazole (n=88), asenapine (n=10), brexpiprazole n=(8), cariprazine (n=10), 
iloperidone (n=6), lurasidone (n=14), paliperidone (n=9), risperidone (n=25), and ziprasidone (n=11). Less 
than half (n=63) of the studies were placebo-controlled. Most of the included studies evaluated patients 
with schizophrenia (n=162), were short-term in duration (12 weeks or less) (n=130), and employed 
flexible dosing (n=122). Some studies reported using the Simpson-Angus Scale (SAS), and/or Abnormal 
Involuntary Movement Scale (AIMS) to measure movement disorders, however all but one study used the 
BARS to assess akathisia specifically. Studies were excluded due to lack of usable data (n=4) or when 
only a single-dose administration was being assessed (n=2). 
Included studies had the following SGA dosage ranges: aripiprazole 2-40 mg/day, aripiprazole long-acting 
injectable (LAI) 50-400 mg/month, aripiprazole lauroxil 441-882 mg/month, asenapine 10-20 mg/day, 
brexpiprazole 0.25-6 mg/day, cariprazine 0.75-12 mg/day, iloperidone 4-24 mg/day, lurasidone 20-160 
mg/day, paliperidone extended-release (ER) 3-15 mg/day, paliperidone palmitate 39-234 mg/month, 
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All of the SGAs produced treatment-emergent akathisia at varying rates (Table 3). Total composite rates 
of akathisia for SGAs ranged from 2.94% to 13.04% across included studies compared to an overall 
incidence of 3.69% for placebo. Of the nine newer SGAs, iloperidone had the lowest incidence of 
akathisia (2.9%), followed by paliperidone palmitate (4.4%), aripiprazole lauroxil (4.5%), brexpiprazole 
(6.3%), and asenapine (6.3%). Middle range medications included paliperidone extended-release (6.6%), 
aripiprazole long-acting injectable (LAI) (8.3%), aripiprazole (8.7%), risperidone LAI (8.9%) and 
ziprasidone (9.0%). Finally, lurasidone (11.2%), cariprazine (13.0%), and risperidone (13.0%) had the 
highest incidences of akathisia. Doses classified as “high” in fixed-dose studies were generally associated 
with an increased risk of akathisia when compared with lower doses of the same drug.
There were no identifiable trends in akathisia rate between the diagnoses of schizophrenia, bipolar 
disorder, and MDD in the studies that were examined in this review (Table 4). The composite rates of 
akathisia in patients being treated for schizophrenia for all SGAs in this review ranged from 2.94% to 
13.03% compared to 4.03% for placebo. Composite incidence of akathisia in patients with bipolar 
disorder with the use of asenapine, cariprazine, lurasidone, and ziprasidone were 7.02%, 14.35%, 8.58%, 
and 10.45%, respectively. Moreover, in comparison to 1.92% incidence of akathisia for placebo, patients 
being treated for MDD experienced a composite akathisia rate of 8.55% with brexpiprazole and 14.47% 
for cariprazine. Cariprazine was the only SGA with studies that reported akathisia rates in all three 
diagnoses examined in this review (with composite rates of 12.1%, 14.4%, and 14.5% for schizophrenia, 
bipolar disorder, and MDD, respectively).
Discussion
Akathisia poses a major treatment challenge in schizophrenia and mood disorders and adds to the health 
burden of these diseases. Quetiapine and clozapine are second generation antipsychotics known to have 
a very low risk of inducing akathisia with rates of 0 to 10% when compared to placebo or other SGAs.3,112-
117 Since the rates of akathisia in these older SGAs have been extensively studied, the focus of this 
review was to assess and compare the incidence of akathisia with nine newer SGAs in patients with 
schizophrenia, bipolar disorder, and MDD. 
Results from this review show that discrepancies in the incidence of akathisia exist even among studies 
of the same antipsychotic, and indicate that further work must be done to better quantify and qualify 
akathisia risk in these medications. These discrepancies can stem from a number of causes, including 
differences in diagnostic approach, measurement parameters and scales used, timing of assessment, 
prior therapies tried, or even when in the course of the disease that a patient is enrolled into the trial. 
While mood disorders have been considered to be a risk factor for akathisia in previous studies,12,111 
antipsychotic doses were generally similar in mood disorder studies when compared to schizophrenia 
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studies that examined akathisia rates in patients with bipolar disorder. Although the rates of akathisia for 
asenapine and ziprasidone were higher in patients treated for bipolar disorder compared to schizophrenia 
(7.0% versus 6.0% for asenapine, and 10.5% versus 8.1% for ziprasidone in bipolar disorder versus 
schizophrenia, respectively), the same trend did not occur in patients taking lurasidone (8.6% versus 
12.3%). Moreover, a higher composite akathisia rate was determined in patients taking brexpiprazole for 
MDD compared to patients being treated for schizophrenia (8.6% versus 5.7%). These results also 
support the growing understanding that SGAs are not benign and clinicians should be monitoring for 
akathisia more regularly in patients taking SGAs.
Notably, the overall incidence of akathisia observed with aripiprazole was much lower than expected 
when compared with other SGAs included in this review, at approximately 8% for both the oral and LAI 
formulations and less than 5% for the lauroxil formulation. Oral and parenteral risperidone produced rates 
of akathisia that were among the highest in this group of SGAs at 13% and 9%, respectively. In contrast, 
akathisia was observed half as often with oral and parenteral paliperidone as with risperidone, though this 
may be attributed to the target and maximum doses of risperidone being much higher relative to 
paliperidone.
Dosing of SGAs can impact akathisia development in patients. A dose-response relationship was evident 
in many of the SGAs with studies evaluating a fixed dose above or below the target dosing range. Oral 
aripiprazole given at higher doses in patients with schizophrenia had a much higher incidence of akathisia 
compared with doses less than 25 mg/day (14.5% versus 8.5%). There was a disparity in akathisia 
incidence between asenapine at high versus target dose in patients with bipolar disorder (15.1% versus 
4.1%), and a smaller disparity between asenapine at high versus target dose in patients with 
schizophrenia (6.9% versus 4.2%). In fixed-dose studies for brexpiprazole, high doses were associated 
with higher incidences of akathisia than target doses (6.9% versus 4.6%) and low doses were likewise 
associated with the lowest incidence of akathisia (2.4%) in patients with schizophrenia. In patients with 
MDD, target doses of brexpiprazole showed higher incidence of akathisia than low doses (10.8% versus 
4.4%). Cariprazine showed a similar dose-related response, with low doses associated with lower 
incidence of akathisia than doses in the target dose range for patients with bipolar disorder (3.8% versus 
14.4%), and low and target doses showing lower rates of akathisia compared to high doses in patients 
with schizophrenia (8.1-9.0% versus 14.7%). Oral paliperidone at high versus target versus low doses 
likewise showed a dose-related effect on incidence of akathisia (9.2% versus 6.5% versus 5.1%) in 
patients with schizophrenia. Lurasidone was the only SGA where a dose-related effect on akathisia was 
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Limitations of this review included a lack of continuity and consensus in assessment and reporting of 
akathisia between the included studies. Some studies used a diagnostic threshold of ≥3 on the BARS 
Global item to assess akathisia, and many others did not explicitly state their methodology for measuring 
akathisia beyond noting the rating scale that was used. Additionally, most trials do not verify systematic 
training or the establishment of interrater reliability for akathisia in published results. Without this, there 
may be discrepancies in scores due to the subjective nature of rating akathisia. Similarly, since akathisia 
ratings are subjective, it should be noted that less than 10% of the studies included in this review were 
open-label studies. Moreover, the concomitant use of antidepressants, antipsychotic polytherapy, or 
pharmacotherapy for akathisia treatment were not consistently reported in the studies that were 
examined. Some trials resulted in multiple publications for post-hoc and sub-analyses which can lead to 
biased composite results. Every effort was made to exclude such post-hoc analyses, however it is 
possible that the same subjects were included more than once in results (eg, with open-label follow-up 
studies). Finally, while our intent was to focus on a comparison of newer agents, another limitation was 
the exclusion of studies examining akathisia rates in patients taking aripiprazole for bipolar disorder or 
MDD, aripiprazole LAI or risperidone LAI for bipolar disorder, and the exclusion of other SGAs from this 
review. Although both aripiprazole LAI and risperidone LAI are indicated for the treatment of bipolar 
disorder, there is a lack of published data on the rates of akathisia for these formulations and indications 
specifically.
Conclusion
SGAs as a class are associated with akathisia. This disorder is often difficult to identify and distinguish 
from other conditions, and there continues to be a lack of information available on the clinical severity, 
timing of onset, and duration of akathisia. Further analysis on the risk of akathisia in individual SGAs is 
needed. Future studies may also evaluate the incidence of akathisia in patients based on established 
cutoff values or mean change in BARS scores, the use of anti-akathisia treatment agents, discontinuation 
rate due to akathisia, and rate of associated adverse reactions such as agitation, tremors, anxiety, or 
other movement disorders. Risk of akathisia must be considered when choosing a treatment option, as 
certain SGAs appear to have lower potential for causing akathisia than others and SGA dosage has been 
found to be associated with rate of akathisia. Clinicians should monitor for akathisia in all patients 
beginning therapy with any of these agents or following a dose increase of the SGA.
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Drug Target dose† (mg/day) Max dose† (mg/day) FDA approved indication(s) for all 
available drug products
aripiprazole20,21 10-30 30 Schizophrenia;
Bipolar disorder;
MDD (adjunct); 
Irritability with autistic disorder; 
Tourette’s disorder
asenapine22 10-20 20 Schizophrenia;
Bipolar disorder
brexpiprazole23 2-4 4 Schizophrenia;
MDD (adjunct)
cariprazine24 1.5-6 6 Schizophrenia;
Bipolar disorder
iloperidone25 12-24 24 Schizophrenia
lurasidone26 40-160 160 Schizophrenia;
Bipolar disorder
paliperidone27,28 3-12 12 Schizophrenia
risperidone29,30 4-8 16 Schizophrenia;
Bipolar disorder; 
Irritability with autistic disorder
ziprasidone31 40-160 200 Schizophrenia;
Bipolar disorder
†Reference dosage from product labeling of oral formulation for schizophrenia.
Table 2. Definitions of low and high doses of oral second-generation antipsychotic drugs13,18
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ziprasidone <120 >150










aripiprazole       
Schizophrenia Fixed High 2 228 33 14.47%
  Target 7 1232 104 8.44%
 Flexible Target 78 5427 463 8.53%
 Total  86 6887 600 8.71%
aripiprazole Total   86 6887 600 8.71%
aripiprazole LAI       
Schizophrenia Fixed Low 1 131 11 8.40%
  Target 2 534 44 8.24%
 Total  3 665 55 8.27%
aripiprazole LAI Total  3 665 55 8.27%
aripiprazole lauroxil       
Schizophrenia Fixed Target 2 893 40 4.48%
 Total  2 893 40 4.48%
aripiprazole lauroxil 
Total
  2 893 40 4.48%
asenapine       
Bipolar Fixed High 1 119 18 15.13%
  Target 1 122 5 4.10%
 Flexible Target 3 884 56 6.33%
 Total  4 1125 79 7.02%
Schizophrenia Fixed High 3 1208 83 6.87%
  Target 3 595 25 4.20%
 Flexible Target 1 572 34 5.94%
 Total  5 2375 142 5.98%
asenapine Total   9 3500 221 6.31%
brexpiprazole       
MDD Fixed Low 1 226 10 4.42%
  Target 2 417 45 10.79%
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Schizophrenia Fixed High 2 364 25 6.87%
  Low 3 252 6 2.38%
  Target 2 368 17 4.62%
 Flexible High 1 93 14 15.05%
  Low 1 89 6 6.74%
  Target 4 1710 97 5.67%
 Total  6 2876 165 5.74%
brexpiprazole Total  8 3519 220 6.25%
cariprazine       
Bipolar Fixed Low 1 287 11 3.83%
  Target 1 146 21 14.38%
 Flexible Target 2 494 101 20.45%
 Total  3 927 133 14.35%
MDD Flexible Low 1 273 18 6.59%
  Target 1 273 61 22.34%
 Total  1 546 79 14.47%
Schizophrenia Fixed High 1 157 23 14.65%
  Low 1 145 13 8.97%
  Target 3 678 55 8.11%
 Flexible High 2 281 37 13.17%
  Target 3 864 129 14.93%
 Total 6 2125 257 12.09%
cariprazine Total   10 3598 469 13.04%
iloperidone       
Schizophrenia Fixed High 2 473 7 1.48%
 Flexible Target 4 3299 104 3.15%
 Total  6 3772 111 2.94%
iloperidone Total   6 3772 111 2.94%
lurasidone       
Bipolar Flexible Target 2 1293 111 8.58%
 Total  2 1293 111 8.58%
Schizophrenia Fixed High 3 285 21 7.37%
  Low 1 71 4 5.63%
  Target 8 1439 190 13.20%
 Flexible Target 4 1122 144 12.83%
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lurasidone Total   14 4210 470 11.16%
paliperidone ER       
Schizophrenia Fixed High 2 468 43 9.19%
  Low 2 254 13 5.12%
  Target 2 605 39 6.45%
 Flexible Target 1 164 3 1.83%
 Total  3 1491 98 6.57%
paliperidone ER 
Total 
  3 1491 98 6.57%
paliperidone palmitate      
Schizophrenia Fixed Target 5 1491 65 4.36%
 Flexible Target 2 985 44 4.47%
 Total 7 2476 109 4.40%
paliperidone 
palmitate Total
  7 2476 109 4.40%
risperidone       
Schizophrenia Fixed Target 10 1069 99 9.26%
  High 1 113 12 10.62%
 Flexible Target 58 4097 577 14.08%
 Total  68 5279 688 13.03%
risperidone Total   68 5279 688 13.03%
risperidone LAI       
Schizophrenia Fixed Target 1 223 44 19.73%
 Flexible Target 3 1155 79 6.84%
 Total  4 1378 123 8.93%
risperidone LAI Total  4 1378 123 8.93%
ziprasidone       
Bipolar Flexible Target 5 1493 156 10.45%
 Total  5 1493 156 10.45%
Schizophrenia Fixed High 2 254 24 9.45%
  Low 2 150 18 12.00%
  Target 2 749 60 8.01%
 Flexible Target 9 1107 81 7.32%
 Total  13 2260 183 8.10%























Bipolar N/A N/A 13 1696 51 3.01%
MDD N/A N/A 3 677 13 1.92%
Schizophrenia N/A N/A 47 6872 277 4.03%
placebo Total   63 9245 341 3.69%
Abbreviations: LAI, long-acting injectable; MDD, major depressive disorder, ER, extended-release.Target doses summarized in 
Table 1, high and low doses summarized in Table 2.






aripiprazole 8.71% - - 8.71%
aripiprazole LAI 8.27% - - 8.27%
aripiprazole lauroxil 4.48% - - 4.48%
asenapine 5.98% 7.02% - 6.31%
brexpiprazole 5.74% - 8.55% 6.25%
cariprazine 12.09% 14.35% 14.47% 13.04%
iloperidone 2.94% - - 2.94%
lurasidone 12.31% 8.58% - 11.16%
paliperidone ER 6.57% - - 6.57%
paliperidone palmitate 4.40% - - 4.40%
risperidone 13.03% - - 13.03%
risperidone LAI 8.93% - - 8.93%
ziprasidone 8.10% 10.45% - 9.03%
placebo 4.03% 3.01% 1.92% 3.69%
Abbreviations: MDD, major depressive disorder.
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